COVID & Flu: Severe Infections Linked to Increased Lung Cancer Risk – Vaccination May Protect

Severe respiratory infections, like COVID-19 and influenza, may carry a long-term risk extending beyond immediate illness. Emerging research suggests a link between severe cases of these infections and an increased risk of lung cancer developing months or even years later, though vaccination appears to offer a significant degree of protection. This finding underscores the importance of continued vigilance and monitoring for those who experienced severe respiratory illness, and reinforces the benefits of preventative measures like vaccination.

Immune System Reprogramming and Cancer Development

Scientists at the University of Virginia (UVA) Health, led by researcher Jie Sun, PhD, have discovered that severe viral infections can fundamentally alter the behavior of immune cells within the lungs. These changes, observed in both laboratory mice and human patients, create an environment that supports tumor growth. Specifically, the research, published in the journal Cell, highlights alterations in neutrophils and macrophages – immune cells normally responsible for defending the lungs – causing them to contribute to chronic inflammation, a known facilitator of cancer development. The study also identified changes in the epithelial cells lining the lungs, further contributing to a “pro-tumor” environment.

The UVA team found a 1.24-fold increase in lung cancer incidence among patients who had been hospitalized for COVID-19. Importantly, this elevated risk was observed regardless of smoking history or the presence of other underlying health conditions, suggesting that the viral infection itself plays a significant role. This finding builds on earlier research indicating that severe inflammation can create conditions conducive to cancer development, even in individuals without traditional risk factors like smoking. As reported by EurekAlert!, the research team is now urging doctors to closely monitor patients who have recovered from severe COVID-19, flu, or pneumonia.

What Does This Indicate for Patients?

The findings do not suggest that everyone who experiences a severe respiratory infection will develop lung cancer. Rather, they indicate a heightened risk for a subset of individuals, particularly those who required hospitalization. The research emphasizes the importance of early detection, as lung cancer is often more treatable in its initial stages. Doctors may consider more frequent or proactive screening – such as low-dose CT scans – for patients with a history of severe respiratory illness, especially those with other risk factors like smoking.

Jeffrey Sturek, MD, PhD, a UVA physician-scientist involved in the study, explained that the findings suggest a need to consider severe respiratory viral infection similarly to smoking when assessing lung cancer risk. “We’ve known for a long time that things like smoking increase the risk for lung cancer,” Sturek said. “The results from this study suggest that we may need to think about severe respiratory viral infection similarly.”

The Protective Role of Vaccination

A key takeaway from the UVA research is the potential protective effect of vaccination. The study demonstrated that prior vaccination appeared to mitigate many of the harmful changes to the lungs linked to cancer development. Vaccines work by priming the immune system to respond more effectively to infection, reducing the severity of illness and, minimizing the long-term inflammatory damage. Individuals who experienced only mild infections did not present the same elevated risk, and in fact, exhibited a slight decrease in lung cancer incidence.

Understanding the Study’s Limitations

While the findings are significant, it’s crucial to acknowledge the study’s limitations. The observed association between severe COVID-19 hospitalization and increased lung cancer incidence does not definitively prove causation. Other factors, not fully accounted for in the analysis, may contribute to the increased risk. Further research is needed to fully elucidate the mechanisms underlying this association and to determine the optimal strategies for monitoring, and prevention.

The study also relied on retrospective data analysis, which can be subject to biases. For example, patients who were hospitalized with severe COVID-19 may have been more likely to receive subsequent medical care, including cancer screening, potentially leading to earlier detection of lung cancer. The researchers addressed this by controlling for known confounding factors, but the possibility of residual bias remains.

Public Health Implications and Ongoing Research

The UVA research has significant implications for public health surveillance and clinical practice. Given that tens of millions of people globally have experienced severe COVID-19, the potential for a future increase in lung cancer incidence is a concern. As reported by Oncology Central, the researchers emphasize the need for enhanced lung cancer surveillance in individuals recovering from severe respiratory infections, particularly those with a history of smoking.

Researchers are now focused on identifying biomarkers that can predict which individuals are at highest risk of developing lung cancer after severe respiratory illness. They are also exploring potential therapeutic interventions to counteract the immune reprogramming observed in the study. The Paul and Diane Manning Institute of Biotechnology at UVA is supporting these efforts, aiming to accelerate the translation of laboratory discoveries into modern treatments.

Next Steps: Enhanced Surveillance and Targeted Prevention

The UVA team hopes their work will inform the development of targeted strategies for preventing and treating lung cancer linked to prior lung infections. This includes refining risk assessment tools, optimizing screening protocols, and exploring novel immunotherapies to restore normal immune function in the lungs. Continued monitoring of lung cancer incidence in populations affected by the COVID-19 pandemic will be crucial to assess the long-term impact of the virus and to guide public health interventions.